Brca | search
Click here to view Brca news from 60+ newspapers.
Bookmark or Share- show more icon - CancerThe project has controlled access data which requires dbGaP Access. See instructions for Obtaining Access to Controlled Data.
- BRCA Gene Changes: Cancer Risk and Genetic TestingThe prevalence of harmful BRCA gene changes in the general population is about 0.2%–0.3% (or about 1 in 400). However, in certain populations that are geographically or culturally distinct, the prevalence of specific BRCA mutations—called founder mutations—is higher.
- Mutaciones en el gen BRCA: el riesgo de cáncer y las pruebas genéticasA veces, los pacientes de cáncer se enteran de que tienen una mutación en BRCA1 o en BRCA2 cuando se examina un tumor para saber si es posible recibir una terapia dirigida específica. Las variantes dañinas en BRCA que se encuentran en un tumor son de origen somático o de la línea germinal.
- Olaparib Approved for Breast Cancers with BRCA Gene MutationsPatients are selected for treatment with olaparib using a companion diagnostic test called BRACAnalysis CDx, which the FDA approved for detecting mutations in BRCA genes in blood samples from patients with breast cancer who may be eligible for olaparib.
- BRCA1 and BRCA2 (PDQ®) - NCI - National Cancer InstituteThe ARIEL-2 phase II study found that rucaparib was effective in the treatment of recurrent, high-grade, platinum-sensitive ovarian cancer in women with BRCA variants, but also in BRCA wild-type women with high genomic loss of heterozygosity (LOH), which is a likely marker of HRD cancers.
More
